



For Immediate Release

Contact: Sue Goin
Sue.Goin@Sapphire-Com.com
317.402.8690

NICO Awards First Investigator Initiated Study Grant to Mayo Clinic
Grant supports physician-led evaluation of MIS technologies on ICH treatment

INDIANAPOLIS, November 14, 2018 – Neurosurgical medical device maker [NICO Corporation](#) has awarded the first grant for its recently funded [Investigator Initiated Study \(IIS\) Program](#) to the Mayo Clinic in Jacksonville, Fla. NICO launched the IIS Program in August to offer financial support for prospective studies or the evaluation of retrospective data related to improved patient and economic outcomes using minimally invasive neurosurgery approaches.

The grant will fund the study of health economics or cost-effectiveness of Minimally Invasive neuroSurgery (MIS) to help future brain hemorrhage patients compared to usual neuro-intensive care. The value of the grant project will be measured using the health economics value equation $V=Q/C$, proving that MIS advances the science and is cost effective by improving outcomes and quality of care, despite higher costs of MIS compared to standard non-invasive standard of care in the ICU.

NICO has been a leader in accumulating clinical research supporting Minimally Invasive Parafascicular Surgery (MIPS) and is now helping to fund research with physician partners who will publish data on scientific signals for efficacy, proof of concept applications, and improved clinical outcomes for patients with abnormalities in the brain.

“We are very excited to award our first grant to Mayo Clinic,” said Penny Sekerak, Vice President of Professional Education and Clinical Affairs for NICO. “The response to the program has been very positive with several inquiries and grant submissions received during the first three months, indicating a strong desire to publish evidence supporting clinical and economic outcomes using new minimally invasive neurosurgery approaches.

“Relative to the grant awarded to Mayo Clinic, their work will help move the field forward to help patients everywhere with ICH disease,” added Sekerak.

NICO’s \$8 million investment supporting true minimally invasive neurosurgery approaches mirrors financing of other neuro-based programs, such as the [Human Connectome Project](#), [Precision Medicine Initiative](#), and [Cancer Moonshot](#). Grant requests for the IIS Program continue to be accepted and will be reviewed for scientific merit, feasibility, possible contribution to the respective body of clinical knowledge, and compatibility with NICO’s long-term clinical and

scientific focus. Only U.S. sites or its territories are eligible. Learn more about the NICO IIS Program and the studies it supports [HERE](#).

[NICO Corporation](#) is a leader in modern interventional technologies used in a new way of performing less invasive brain surgery for subcortical and skull base lesions, intraventricular tumors and cysts, and hemorrhagic stroke. It is an outcomes-based company dedicated to revolutionizing minimally invasive neurosurgery through evidence-based, improved clinical and economic outcomes. More than [65 peer-reviewed independent papers, posters and abstracts](#) have been published on improved clinical outcomes for appropriate patients and economic benefit to the healthcare institution using the technologies.

Learn about [NICO technologies](#) at [NICOneuro.com](#); follow news updates on [LinkedIn](#) and view surgical and patient videos on YouTube at [NICOneuroCorp.](#)